-$0.25 Earnings Per Share Expected for Dynavax Technologies Co. (NASDAQ:DVAX) This Quarter

Wall Street analysts forecast that Dynavax Technologies Co. (NASDAQ:DVAX) will post ($0.25) earnings per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Dynavax Technologies’ earnings, with the lowest EPS estimate coming in at ($0.32) and the highest estimate coming in at ($0.18). Dynavax Technologies posted earnings of ($0.66) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 62.1%. The business is scheduled to announce its next earnings report on Wednesday, August 5th.

According to Zacks, analysts expect that Dynavax Technologies will report full-year earnings of ($0.98) per share for the current financial year, with EPS estimates ranging from ($1.00) to ($0.96). For the next fiscal year, analysts forecast that the business will report earnings of ($0.46) per share, with EPS estimates ranging from ($0.67) to ($0.12). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Dynavax Technologies.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings results on Wednesday, March 11th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.11). Dynavax Technologies had a negative net margin of 310.97% and a negative return on equity of 722.75%. The business had revenue of $10.57 million for the quarter, compared to analyst estimates of $11.92 million.

A number of equities research analysts recently weighed in on the company. William Blair reaffirmed a “buy” rating on shares of Dynavax Technologies in a report on Friday, March 13th. ValuEngine raised Dynavax Technologies from a “hold” rating to a “buy” rating in a report on Tuesday, April 7th. BidaskClub cut Dynavax Technologies from a “hold” rating to a “sell” rating in a report on Thursday, May 14th. Zacks Investment Research lowered Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, May 26th. Finally, HC Wainwright reiterated a “buy” rating and issued a $12.00 price objective on shares of Dynavax Technologies in a research report on Sunday, March 29th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. Dynavax Technologies currently has a consensus rating of “Buy” and a consensus target price of $12.75.

DVAX stock traded down $0.74 during midday trading on Tuesday, reaching $7.18. 16,919,309 shares of the company’s stock traded hands, compared to its average volume of 3,256,393. The company has a 50-day simple moving average of $4.28 and a two-hundred day simple moving average of $4.85. Dynavax Technologies has a 1-year low of $1.80 and a 1-year high of $8.12. The company has a market cap of $679.27 million, a price-to-earnings ratio of -4.00 and a beta of 1.14. The company has a quick ratio of 4.99, a current ratio of 6.63 and a debt-to-equity ratio of 18.31.

In related news, Director Andrew A. F. Hack purchased 1,000,000 shares of Dynavax Technologies stock in a transaction dated Wednesday, May 27th. The shares were acquired at an average cost of $4.84 per share, for a total transaction of $4,840,000.00. Also, SVP Robert Janssen sold 15,000 shares of the firm’s stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $6.33, for a total value of $94,950.00. Following the completion of the transaction, the senior vice president now owns 177,266 shares in the company, valued at $1,122,093.78. The disclosure for this sale can be found here. 13.33% of the stock is currently owned by company insiders.

Large investors have recently bought and sold shares of the company. NumerixS Investment Technologies Inc bought a new position in shares of Dynavax Technologies in the 4th quarter worth $41,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Dynavax Technologies by 176.6% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,318 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 5,311 shares during the last quarter. Panagora Asset Management Inc. bought a new position in shares of Dynavax Technologies in the 4th quarter worth $53,000. ProShare Advisors LLC bought a new position in shares of Dynavax Technologies in the 4th quarter worth $65,000. Finally, Quantitative Investment Management LLC bought a new position in shares of Dynavax Technologies in the 1st quarter worth $46,000. Institutional investors and hedge funds own 67.05% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.

Recommended Story: What is the Shanghai Stock Exchange Composite Index?

Get a free copy of the Zacks research report on Dynavax Technologies (DVAX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.